Osteomyelitis

Table of Contents

  1. Overview
  2. Classification and Routes of Infection
  3. Pathophysiology
  4. Microbiology
  5. Clinical Presentation
  6. Diagnosis
  7. Antibiotic Treatment
  8. Surgical Management
  9. Complications and Prognosis
  10. Key Research Papers
  11. PubMed Research Searches
  12. Connections
  13. Featured Videos

1. Overview

Osteomyelitis is an infection of bone — one of the most difficult-to-treat infections in medicine because bone is a rigid compartment with limited blood supply, making it hard for antibiotics to penetrate and the immune system to clear bacteria once they establish themselves. Infected bone can die (form a sequestrum), shield bacteria from antibiotics inside a protein-coated biofilm, and generate an intense inflammatory response that paradoxically worsens local ischemia and damage.

The condition spans a wide spectrum from an acute, hematogenously seeded metaphyseal infection in a healthy child — treatable with 4–6 weeks of antibiotics — to a decades-long chronic infection with draining sinus tracts, recurrent abscesses, and dead bone that can only be managed with radical surgical debridement. Understanding which category a patient falls into determines the entire treatment strategy: who can be managed medically, who needs surgery, and for how long antibiotics must be continued.

Osteomyelitis is not rare. It occurs in approximately 2–13 per 100,000 people per year in developed countries, with incidence rising due to the global epidemics of diabetes and intravenous drug use, the growing population of immunocompromised patients, and the increasing use of orthopedic hardware (joint replacements, spinal instrumentation, fracture fixation devices) that provides surfaces for biofilm formation.

2. Classification and Routes of Infection

The most clinically useful classification system divides osteomyelitis by route of bacterial entry:

Hematogenous osteomyelitis

Bacteria reach bone via the bloodstream from a distant site — a urinary tract infection, intravenous catheter, skin furuncle, endocarditis, or occult bacteremia. This is the classic route in children, where the anatomy of the metaphyseal microvasculature creates a uniquely susceptible niche:

In adults, hematogenous seeding most commonly targets the vertebral bodies (vertebral osteomyelitis / spondylodiscitis), reflecting the rich arterial supply of the vertebral end-plates. The infection typically begins at the end-plate, spreads across the disc space to the adjacent vertebral body, and can extend into the epidural space causing an abscess that threatens the spinal cord.

Contiguous-focus osteomyelitis

Bacteria reach bone from an adjacent soft-tissue infection. The classic example is the diabetic foot: a plantar ulcer overlying a bony prominence becomes chronically infected; bacteria erode through soft tissue to invade the underlying metatarsal or phalanx. Vascular disease and peripheral neuropathy (reducing pain sensation and impairing wound healing) make this catastrophically common in patients with diabetes. A probe-to-bone test (gently probing an ulcer with a blunt metal instrument and feeling the hard gritty texture of bone) has >85% positive predictive value for osteomyelitis in diabetic foot ulcers.

Direct inoculation osteomyelitis

Open fractures, penetrating trauma (lawn-mower injuries, gun-shot wounds), bite wounds, and orthopedic procedures (joint replacement, internal fixation of fractures, spinal surgery) introduce bacteria directly into bone. Post-surgical osteomyelitis is classified by timing: early (<3 months), delayed (3–24 months), and late (>24 months). Biofilm formation on hardware is the central challenge; most cases of implant-associated osteomyelitis require hardware removal for cure.

Duration classification

Osteomyelitis is also classified by duration:

3. Pathophysiology

Once bacteria establish a foothold in bone, a destructive cycle begins:

  1. Bacterial seeding and initial multiplication. S. aureus is particularly adept at bone invasion — it expresses surface adhesins (fibronectin-binding proteins, bone sialoprotein receptors) that allow it to attach to bone matrix proteins. The bacteria initially proliferate in a planktonic (free-floating) state before transitioning to biofilm communities embedded in polysaccharide matrix.
  2. Inflammatory response and ischemia. Bacterial products activate the innate immune response, triggering a massive neutrophil influx and cytokine release (IL-1, IL-6, TNF-α). The resulting edema and purulent exudate raise intraosseous pressure, compressing the already tenuous cortical blood supply. Subperiosteal pus strips the periosteum from the cortex, further disrupting the outer cortical blood supply.
  3. Cortical necrosis and sequestrum formation. Segments of cortical bone that lose their blood supply die, becoming a sequestrum — a fragment of avascular dead bone that cannot be resorbed by the body and acts as a protected reservoir for bacteria.
  4. Involucrum. The periosteum attempts to wall off the infection by forming new reactive bone around the infected area, creating a shell of new bone called the involucrum. Openings in the involucrum (cloacae) allow pus and bone fragments to drain to the skin surface through sinus tracts, the hallmark of chronic osteomyelitis.
  5. Biofilm persistence. Bacteria within the sequestrum exist in slow-metabolizing biofilm communities, expressing drastically reduced susceptibility to antibiotics (minimum biofilm eradication concentrations can be 100–1000 times higher than planktonic minimum inhibitory concentrations). This is why antibiotics alone rarely cure chronic osteomyelitis with established sequestrum — the dead bone must be surgically removed.

4. Microbiology

The causative organism varies considerably with patient age, risk factors, and route of infection:

5. Clinical Presentation

Hematogenous osteomyelitis in children

Classic presentation is a febrile child (temperature >38.5°C) with acute onset of focal bone pain, tenderness, and unwillingness to use the affected limb. The overlying soft tissue is typically swollen and warm. In neonates, the presentation can be subtle — pseudoparalysis (refusing to move the limb), irritability, and failure to thrive without striking fever. Neonatal osteomyelitis often involves multiple bones simultaneously and can spread rapidly to adjacent joint spaces causing concurrent septic arthritis.

Vertebral osteomyelitis in adults

The classic triad is back pain + fever + elevated inflammatory markers, but the presentation is frequently indolent and non-specific. Important points:

Diabetic foot osteomyelitis

The challenge here is that osteomyelitis often coexists with Charcot neuroarthropathy and neuropathic ulceration in a limb that lacks pain sensation. Swelling, redness, warmth, and purulent drainage from a foot ulcer are the presenting features. The clinician must determine whether the underlying bone is infected, inflamed from Charcot changes, or both.

6. Diagnosis

Laboratory studies

Inflammatory markers — ESR and CRP — are elevated in the vast majority of cases and are useful for both diagnosis and monitoring treatment response (CRP normalizes within 2–3 weeks of effective therapy; ESR lags, normalizing over 3–4 weeks). White blood cell count is elevated in only about 50% of cases and is an unreliable sole marker. Procalcitonin (PCT) has high specificity for bacterial infection and is increasingly used.

Blood cultures should be obtained before starting antibiotics in all cases of suspected hematogenous osteomyelitis. They are positive in approximately 50–70% of pediatric hematogenous cases and 30–50% of vertebral osteomyelitis cases. If positive, they may spare the patient a bone biopsy.

Imaging

Bone biopsy and culture

Microbiologic identification of the causative organism is essential for targeted antibiotic therapy. In the absence of positive blood cultures, bone biopsy is required. For vertebral osteomyelitis, CT-guided percutaneous biopsy has a diagnostic yield of approximately 30–50% — higher when antibiotics have not been given. If initial biopsy is negative and blood cultures are also negative, antibiotics should be held and biopsy repeated before committing to empiric long-course therapy. Surgical biopsy at debridement provides specimens with higher yield and allows direct assessment of tissue viability.

7. Antibiotic Treatment

The cornerstone of osteomyelitis treatment is prolonged antibiotic therapy tailored to the causative organism and its susceptibility profile. Key principles:

Duration

Standard duration for uncomplicated hematogenous osteomyelitis is 4–6 weeks. The OVIVA trial (PMID 30073941), a landmark UK multicenter RCT published in 2019, demonstrated that oral antibiotic therapy is non-inferior to IV therapy for the primary outcome (treatment failure at 1 year) in bone and joint infections when an appropriate oral agent with good bone bioavailability is available. This has changed practice significantly, enabling earlier step-down from IV to oral antibiotics and reducing the burden of prolonged intravenous access.

Empiric therapy

Empiric antibiotics should be chosen based on the most likely organisms while awaiting culture results:

Monitoring response

CRP and ESR should be measured every 1–2 weeks. CRP declining toward normal by weeks 2–3 strongly suggests an adequate clinical response. Rising or persistently elevated CRP during therapy suggests treatment failure: inadequate antibiotic coverage, undrained abscess, unresected sequestrum, or biofilm infection on hardware. MRI should be repeated at 6–8 weeks to assess response when diagnosis was vertebral osteomyelitis.

8. Surgical Management

Not all osteomyelitis requires surgery, but several indications are clear:

Dead-space management after radical debridement is a key surgical challenge. Options include antibiotic-impregnated calcium sulfate or hydroxyapatite beads (release high local antibiotic concentrations), muscle flap coverage (imports vascularized tissue to a poorly perfused area), and bone transport via the Ilizarov method for large segmental defects.

9. Complications and Prognosis

Osteomyelitis carries a significant risk of severe complications if not treated promptly and appropriately:

Prognosis for acute hematogenous osteomyelitis in children treated promptly is excellent, with cure rates exceeding 90%. Vertebral osteomyelitis has favorable outcomes in 70–85% of patients who complete appropriate treatment, though neurologic recovery depends on the severity and duration of cord compression. Diabetic foot osteomyelitis has the most guarded prognosis; major amputation rates approach 20–30% at 5 years.

10. Key Research Papers

  1. Li et al. (OVIVA trial), 2019 — PMID: 30073941 — Landmark RCT: oral antibiotics non-inferior to IV for bone and joint infection at 1 year; changed practice toward earlier oral step-down.
  2. Lew and Waldvogel, 2004 — PMID: 15350226 — Comprehensive seminal review of osteomyelitis classification, pathogenesis, and management framework; foundational reference.
  3. Berbari et al. (IDSA Guidelines), 2015 — PMID: 26209005 — IDSA clinical practice guidelines for vertebral osteomyelitis in adults; imaging, diagnosis, and treatment duration recommendations.
  4. Karamanis et al., 2020 — PMID: 32259492 — Systematic review of FDG-PET/CT for osteomyelitis; pooled sensitivity 96%, specificity 91%, superior to bone scan.
  5. Berendt et al., 2011 — PMID: 21546560 — Probe-to-bone test for diabetic foot osteomyelitis: positive predictive value >85%; simple bedside diagnostic tool.
  6. Zimmerli, 2010 — PMID: 23140267 — Vertebral osteomyelitis review: pathogenesis, MRI gold standard findings, antibiotic duration, and surgical indications.
  7. McNally et al., 2016 — PMID: 26953482 — Unified classification system for osteomyelitis (Unified Classification System); proposed framework integrating host, bone quality, and local wound factors.
  8. Grammatico-Guillon et al., 2012 — PMID: 22784797 — Epidemiology of vertebral osteomyelitis in France: incidence 2.2/100,000/yr; risk factors DM, IVDU, age; 3-month mortality 6%.
  9. Senneville et al., 2017 — PMID: 29092924 — Management of diabetic foot osteomyelitis; systematic review supporting medical vs. surgical decision-making framework.
  10. Berbari et al., 2015 — PMID: 25901016 — Outcome predictors in vertebral osteomyelitis: neurologic deficit and abscess size drive need for surgery.
  11. Spellberg and Lipsky, 2012 — PMID: 22100570 — Systemic antibiotic therapy for chronic osteomyelitis: evidence review; supports oral agents with adequate bioavailability as definitive therapy.
  12. Peltola and Pääkkönen, 2014 — PMID: 24447463 — Pediatric hematogenous osteomyelitis: clinical features, S. aureus dominance, and evidence for short-course IV-to-oral transition.

11. PubMed Research Searches

The links below run live searches on PubMed, the U.S. National Library of Medicine's database of biomedical literature.

  1. Osteomyelitis antibiotic treatment outcomes
  2. Vertebral osteomyelitis MRI diagnosis
  3. Diabetic foot osteomyelitis
  4. Pediatric hematogenous osteomyelitis
  5. MRSA osteomyelitis treatment
  6. Chronic osteomyelitis surgical debridement
  7. Oral antibiotics bone joint infection OVIVA
  8. Implant-associated osteomyelitis biofilm
  9. Tuberculous spondylitis Pott disease
  10. Sickle cell disease osteomyelitis Salmonella
  11. FDG-PET CT osteomyelitis diagnosis
  12. Osteomyelitis bone biopsy culture yield

Connections

Back to Table of Contents